TrovaGene, Inc. (TROV)
|Net Income (ttm)||n/a|
|Trading Day||May 7, 2020|
|Day's Range||1.16 - 1.19|
|52-Week Range||0.70 - 3.46|
Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.
TrovaGene Inc (NASDAQ: TROV) shares, which had been on a downtrend since early April, reversed course in mid-August.
TrovaGene announced that it had achieved a positive finding using its drug onvansertib in combination with AbbVie's Venclexta in relapsed or refractory AML patients.
It's déjà vu for biotech investors, who witnessed a wild rally in Bio-Path Holdings Inc (NASDAQ: BPTH) this week.
Trovagene, a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The onvansertib is also in Phase II ... [Read more...]
Thomas H. Adams
|Stock Exchange |
|Ticker Symbol |